Replimune Group, Inc. Stock News

NEW YORK--(BUSINESS WIRE)---- $REPL #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruq...

NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the "Class Period"), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options

One day after enduring a nearly 40% decline in its share price, bitoech Replimune (REPL -6.79%) was also down on Friday, although nowhere near as steeply. The company's stock was in the red by almost 7%, which didn't look so hot next to the S&P 500's (^GSPC 0.49%) gain of 0.5%.

On Thursday, Replimune (REPL -39.41%) had a crucial meeting with federal regulators regarding one of its leading drug candidates. While the outcome of the event wasn't necessarily negative, it left the future of the drug up in the air, and investors didn't like that uncertainty.

Investors can contact the law firm at no cost to learn more about recovering their losses

BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Block & Leviton reminds investors that a securities fraud lawsuit has been filed against Replimune Group, Inc. (Nasdaq: REPL) and certain of its executives.